Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions

Ping Chih Hsu, Li Chung Chiu, Shih Hong Li, Chih Hung Chen, Chih Liang Wang, Kuo Chin Kao, John Wen Chang Chang, Chih Wei Wang, Chih Teng Yu, Fu Tsai Chung, Cheng Ta Yang, Chien Ying Liu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background In this study, we investigated the efficacy of continuous epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) administration in lung adenocarcinoma patients harboring favorable mutations regarding the progressive disease (PD) status with appearance of indolent new lesions. Methods From June 2010 to October 2012, 102 patients with lung adenocarcinoma, harboring favorable EGFR mutations and treated with EGFR-TKI were analyzed. Definite new lesions were detected during EGFR-TKI therapy, even though the primary target tumors were controlled. Results Of the 102 patients, 57 continued and 45 discontinued EGFR-TKI therapy. The median overall survival was 529 days for the discontinuation group and 791 days for the continuation group (p = 0.0197). Median survival time after the discontinuation of EGFR-TKI was 181 days and 115 days in the discontinuation and continuation groups, respectively (p = 0.1776), whereas median survival time after the appearance of indolent new lesions was 204 days and 262 days, respectively (p = 0.0237). Conclusion Continuous EGFR-TKI administration in favorable EGFR-mutative lung adenocarcinoma patients with controlled primary tumors did not hinder the survival benefit, despite the appearance of new lesions.

Original languageEnglish
Pages (from-to)121-129
Number of pages9
JournalBiomedical Journal
Volume39
Issue number2
DOIs
Publication statusPublished - Apr 1 2016
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Lung
Mutation
Survival
Neoplasms
Adenocarcinoma of lung
Therapeutics

Keywords

  • Epidermal growth factor receptor-tyrosine kinase inhibitor
  • Overall survival
  • Progression-free survival
  • Progressive disease
  • Response Evaluation Criteria in Solid Tumors

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions. / Hsu, Ping Chih; Chiu, Li Chung; Li, Shih Hong; Chen, Chih Hung; Wang, Chih Liang; Kao, Kuo Chin; Chang, John Wen Chang; Wang, Chih Wei; Yu, Chih Teng; Chung, Fu Tsai; Yang, Cheng Ta; Liu, Chien Ying.

In: Biomedical Journal, Vol. 39, No. 2, 01.04.2016, p. 121-129.

Research output: Contribution to journalArticle

Hsu, Ping Chih ; Chiu, Li Chung ; Li, Shih Hong ; Chen, Chih Hung ; Wang, Chih Liang ; Kao, Kuo Chin ; Chang, John Wen Chang ; Wang, Chih Wei ; Yu, Chih Teng ; Chung, Fu Tsai ; Yang, Cheng Ta ; Liu, Chien Ying. / Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions. In: Biomedical Journal. 2016 ; Vol. 39, No. 2. pp. 121-129.
@article{a9ebe1fe42d2442badf679f9c4ac7e23,
title = "Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions",
abstract = "Background In this study, we investigated the efficacy of continuous epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) administration in lung adenocarcinoma patients harboring favorable mutations regarding the progressive disease (PD) status with appearance of indolent new lesions. Methods From June 2010 to October 2012, 102 patients with lung adenocarcinoma, harboring favorable EGFR mutations and treated with EGFR-TKI were analyzed. Definite new lesions were detected during EGFR-TKI therapy, even though the primary target tumors were controlled. Results Of the 102 patients, 57 continued and 45 discontinued EGFR-TKI therapy. The median overall survival was 529 days for the discontinuation group and 791 days for the continuation group (p = 0.0197). Median survival time after the discontinuation of EGFR-TKI was 181 days and 115 days in the discontinuation and continuation groups, respectively (p = 0.1776), whereas median survival time after the appearance of indolent new lesions was 204 days and 262 days, respectively (p = 0.0237). Conclusion Continuous EGFR-TKI administration in favorable EGFR-mutative lung adenocarcinoma patients with controlled primary tumors did not hinder the survival benefit, despite the appearance of new lesions.",
keywords = "Epidermal growth factor receptor-tyrosine kinase inhibitor, Overall survival, Progression-free survival, Progressive disease, Response Evaluation Criteria in Solid Tumors",
author = "Hsu, {Ping Chih} and Chiu, {Li Chung} and Li, {Shih Hong} and Chen, {Chih Hung} and Wang, {Chih Liang} and Kao, {Kuo Chin} and Chang, {John Wen Chang} and Wang, {Chih Wei} and Yu, {Chih Teng} and Chung, {Fu Tsai} and Yang, {Cheng Ta} and Liu, {Chien Ying}",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.bj.2015.07.002",
language = "English",
volume = "39",
pages = "121--129",
journal = "Biomedical Journal",
issn = "2319-4170",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "2",

}

TY - JOUR

T1 - Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions

AU - Hsu, Ping Chih

AU - Chiu, Li Chung

AU - Li, Shih Hong

AU - Chen, Chih Hung

AU - Wang, Chih Liang

AU - Kao, Kuo Chin

AU - Chang, John Wen Chang

AU - Wang, Chih Wei

AU - Yu, Chih Teng

AU - Chung, Fu Tsai

AU - Yang, Cheng Ta

AU - Liu, Chien Ying

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Background In this study, we investigated the efficacy of continuous epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) administration in lung adenocarcinoma patients harboring favorable mutations regarding the progressive disease (PD) status with appearance of indolent new lesions. Methods From June 2010 to October 2012, 102 patients with lung adenocarcinoma, harboring favorable EGFR mutations and treated with EGFR-TKI were analyzed. Definite new lesions were detected during EGFR-TKI therapy, even though the primary target tumors were controlled. Results Of the 102 patients, 57 continued and 45 discontinued EGFR-TKI therapy. The median overall survival was 529 days for the discontinuation group and 791 days for the continuation group (p = 0.0197). Median survival time after the discontinuation of EGFR-TKI was 181 days and 115 days in the discontinuation and continuation groups, respectively (p = 0.1776), whereas median survival time after the appearance of indolent new lesions was 204 days and 262 days, respectively (p = 0.0237). Conclusion Continuous EGFR-TKI administration in favorable EGFR-mutative lung adenocarcinoma patients with controlled primary tumors did not hinder the survival benefit, despite the appearance of new lesions.

AB - Background In this study, we investigated the efficacy of continuous epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) administration in lung adenocarcinoma patients harboring favorable mutations regarding the progressive disease (PD) status with appearance of indolent new lesions. Methods From June 2010 to October 2012, 102 patients with lung adenocarcinoma, harboring favorable EGFR mutations and treated with EGFR-TKI were analyzed. Definite new lesions were detected during EGFR-TKI therapy, even though the primary target tumors were controlled. Results Of the 102 patients, 57 continued and 45 discontinued EGFR-TKI therapy. The median overall survival was 529 days for the discontinuation group and 791 days for the continuation group (p = 0.0197). Median survival time after the discontinuation of EGFR-TKI was 181 days and 115 days in the discontinuation and continuation groups, respectively (p = 0.1776), whereas median survival time after the appearance of indolent new lesions was 204 days and 262 days, respectively (p = 0.0237). Conclusion Continuous EGFR-TKI administration in favorable EGFR-mutative lung adenocarcinoma patients with controlled primary tumors did not hinder the survival benefit, despite the appearance of new lesions.

KW - Epidermal growth factor receptor-tyrosine kinase inhibitor

KW - Overall survival

KW - Progression-free survival

KW - Progressive disease

KW - Response Evaluation Criteria in Solid Tumors

UR - http://www.scopus.com/inward/record.url?scp=84978476953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978476953&partnerID=8YFLogxK

U2 - 10.1016/j.bj.2015.07.002

DO - 10.1016/j.bj.2015.07.002

M3 - Article

C2 - 27372167

AN - SCOPUS:84978476953

VL - 39

SP - 121

EP - 129

JO - Biomedical Journal

JF - Biomedical Journal

SN - 2319-4170

IS - 2

ER -